AI Clinical Trials

In clinical development, AI is no longer a question of whether it works, but of which layer the value lands on. The first revenue does not flow to fully autonomous clinical AI, but to modules embedded in the workflow that connect to real data and remain auditable: patient screening, trial feasibility, site selection, EDC/eCOA/eTMF, risk-based monitoring, RWD/RWE, pharmacovigilance, and partial document automation. The profit pool sits in workflow control (Veeva subscriptions; Medidata/Oracle/Medable platform fees), data access (Tempus, TriNetX, Truveta, Flatiron, Aetion), and compliance capability. AI clearly compresses operational time (Syneos site startup from months to 24-48h; Flatiron 37 seconds per CRF; Medidata listing generation -90%, review -80%; Medable eCOA build from days to 30 minutes), but the evidence that it shortens biological-uncertainty time or lowers failure rates remains weak. The FDA released its AI decision-support guidance framework in 2025, pushing the sector into a phase of dual regulatory and commercial validation. Rating Overweight: a value chain where data uniqueness, workflow depth, compliance, and clean billing decide who captures the durable profit pool.